-
Putin denies plan for new Russia military call up
-
Grief on Chinese internet as wait for Tibet flood news drags on
-
Caruana Galizia: 'one-woman WikiLeaks' who exposed Malta's shady side
-
Heavy rain puts a dampener on Taiwan 'extreme heat' drill
-
Kuwait's Iranians under pressure since start of war
-
Juve's Khephren Thuram out until 2027 with knee injury
-
EU lawmakers demand Brussels force Meta to 'protect' European children
-
Delivering aid to Nepal flood survivors 'very, very difficult': UN
-
Clooney turns AFP photographer in jokey red carpet switch
-
German growth prospects brighten as economy defies Mideast turmoil
-
Retirement Income Planning Florida Launches No-Cost 'Income Gap Analysis' Program for Pre-Retirees
-
Outrage mounts in Malta after acquittal over journalist's murder
-
Iraola hails Barcola mentality after blockbuster Liverpool move
-
Malaysia starts cloud seeding to help clear toxic haze
-
Michelsen shocks Nakashima in US Open clash of rising Americans
-
El Nino could be strongest in decades, UN warns
-
US govt sides with OpenAI in New York Times copyright lawsuit
-
Kenya steps up crocodile hunt as rising lakes fuel conflict
-
Grammy-Winning Jazz Vocalist Cassandra Wilson Dies at 70
-
Argentine Groups Seek Court Halt to Sea Lion Oil Project Near Falklands
-
Maui Wildfire Survivors Report Major Losses to Troubled Rebuilding Contractors
-
China’s Oil Use Drops 9 Percent as Transport Electrification Accelerates
-
WMO Says Powerful El Niño Is Likely to Persist Into February 2027
-
Fifth-Generation Mitsubishi Pajero Returns With Ladder Frame and Seven Seats
-
Honda Presses Suppliers for Deep Cost Cuts in $9.4 Billion Savings Drive
-
Philadelphia Roundup: Museum Closure, Phishing Warning and Gun Violence Data
-
Philadelphia Festival Revisits the Signing and Legacy of the U.S. Constitution
-
Philadelphia Natural History Museum Prepares to Close After Two Centuries
-
Russia to close branches of Germany's Goethe Institute
-
Indonesia protesters targeted by coordinated disinfo
-
Spacecraft bound for Mercury faces 'tricky' arrival
-
Oil sinks, bond yields ease and stocks boosted after Trump Iran hint
-
Philippines holds drills to safeguard students from armed intruders
-
American jazz singer Cassandra Wilson dies at 70
-
In Ghana, larger-than-life coffins tell the stories of the dead
-
Rare trio of Pacific hurricanes fueled by historic El Nino
-
Menoncello, Reece headline Top 14 new-season signings
-
Chinese WNBA star out of World Cup after losing passport
-
Families descend on Nepal in search of missing tourists
-
Medieval Europe and Africa collide in Sao Tome traditional theatre
-
Far-right AfD eyes huge win in east German state vote
-
Iran attacks US targets despite Trump threats
-
Brazil-Japan to play World Cup rematch at Singapore tournament
-
Alcaraz believes 'impossible' schedule raising injury threat
-
Defence chiefs back boosting US military presence in Australia
-
Alcaraz rallies to reach US Open third round, Sabalenka storms through
-
Nepal seeks climate justice after Himalayan disaster
-
Alcaraz overpowers Faria to reach US Open third round
-
Stocks rise, yields ease as oil slips on Trump hint at short bombing campaign
-
Hamilton hopes to boost title bid with record Italian triumph
CV Sciences, Inc. To Announce Year End and Fourth Quarter 2024 Results On March 27, 2025
SAN DIEGO, CALIFORNIA / ACCESS Newswire / March 20, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extracts and other proven, science-backed natural ingredients and products, today announced that it will release financial results for the year end and fourth quarter ended December 31, 2024, before the stock market opens on Thursday, March 27, 2025. The Company will hold a conference call with the investment community at 7:00 a.m. Pacific Time (10:00 a.m. Eastern Time) that same day.
The webcast of the conference call will be available on the Investor Relations section of the Company's website at https://ir.cvsciences.com/news-events or directly at https://viavid.webcasts.com/starthere.jsp?ei=1710928&tp_key=ccf1cdb9ed. The webcast will be archived for approximately 30 days. Investors interested in participating in the live call can also dial (877) 407-0784 from the U.S. or international callers can dial (201) 689-8560. Please dial the conference telephone number 15 minutes prior to the start time due to increased demand for conference calls.
A telephone replay will be available approximately two hours after the call concludes and will be available through Thursday, April 3, 2025, by dialing (844) 512-2921 from the U.S. or (412) 317-6671 from international locations, and entering confirmation code 13752212.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB:CVSI) is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company's hemp extracts and other proven, science-backed, natural ingredients and products are sold through a range of sales channels from B2B to B2C. The Company's +PlusCBD™ branded products are sold at select retail locations throughout the U.S. and are the top-selling hemp-extract brand in the natural products market, according to SPINS, the leading provider of syndicated data and insights for the natural, organic and specialty products industry. With a commitment to science, PlusCBD™ product benefits in healthy people are supported by human clinical research data, in addition to three published clinical case studies available on PubMed.gov. +PlusCBD™ was the first hemp extract supplement brand to invest in the scientific evidence necessary to receive self-affirmed Generally Recognized as Safe (GRAS) status. The Company also produces cannabinoid-free supplements under its +PlusHLTH™ brand, with targeted formulations to optimize health, improve performance, and increase vitality. Our Cultured Foods™ brand provides a variety of 100% plant-based food products that are distributed primarily in the EU and other select markets. Cultured Foods™ caters to individuals seeking vegan, gluten-free, or flexitarian options for a wholesome and satisfying culinary experience. In addition, the Company owns Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry. CV Sciences, Inc. has primary offices and facilities in San Diego, California, Grand Junction, Colorado, and Warsaw, Poland. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risk and uncertainties. CV Sciences does not undertake any obligation to publicly update any forward-looking statements, except as required by applicable law. As a result, investors should not place undue reliance on such forward-looking statements.
CONTACT INFORMATION:
SOURCE: CV Sciences, Inc.
View the original press release on ACCESS Newswire
J.Gomez--AT